RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 82.6%

Neg 82.6% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.